Hospital Universitario Infanta Sofía
- Address
- lock Available on a paid plan
Hematology and Blood Cancers
At Hospital Universitario Infanta Sofía, the Hematología team is involved in studies focused on hemic and lymphatic diseases and neoplasms, with a strong emphasis on improving outcomes for people with acute myeloid leukemia, newly-diagnosed multiple myeloma, and metastatic castration-resistant prostate cancer. These trials are designed to test new treatment approaches and compare them with current standards of care.
- New treatment strategies for acute myeloid leukemia and other blood cancers
- Research in newly-diagnosed multiple myeloma aimed at deepening response to therapy
- Studies in advanced solid tumors such as metastatic castration-resistant prostate cancer
The site also contributes to research in breast cancer, endometrial cancer, ovarian cancer, and bladder cancer, reflecting a broad oncology portfolio.
Cardiovascular and Thrombotic Disease Research
Clinical trials at this site address cardiovascular diseases and blood-clotting disorders, including acute heart failure, acute pulmonary embolism, deep vein thrombosis, hypertension, and atherosclerotic cardiovascular disease. The main goal is to evaluate therapies that may improve symptom control, reduce complications, and lower long-term cardiovascular risk.
- Studies testing better care for acute pulmonary embolism and thrombolysis of symptomatic proximal vein thrombosis
- Research in heart failure focused on improving decongestion and recovery
- Trials in hypertension and high cardiovascular risk aimed at preventing major events
Work in this area includes efforts to improve treatment effectiveness for patients with established vascular disease and to support safer, more personalized cardiovascular care.
Autoimmune, Neuromuscular, and Inflammatory Disorders
The site is active in immune system diseases and nervous system diseases, with studies in systemic lupus erythematosus, ANCA-associated vasculitis, and generalized myasthenia gravis. These trials aim to assess new therapies that may better control disease activity, reduce flare-ups, and improve daily functioning.
- Research in systemic lupus erythematosus to improve disease control and safety
- Studies in generalized myasthenia gravis focused on muscle strength and symptom relief
- Trials in ANCA-associated vasculitis evaluating treatment safety and effectiveness
This therapeutic area highlights a strong interest in chronic inflammatory conditions where more precise and better-tolerated treatments are needed.
Dermatology, Allergy, and Eye Disease Studies
Research at Hospital Universitario Infanta Sofía also covers skin and connective tissue diseases, respiratory tract diseases, and eye diseases. Trials include atopic dermatitis, allergic rhinoconjunctivitis, and non-infectious uveitis, with the purpose of improving symptom control and testing targeted immunotherapy approaches.
- Studies in atopic dermatitis evaluating better control of skin inflammation and itching
- Allergy research in allergic rhinoconjunctivitis and pollen sensitization
- Eye disease trials in non-infectious uveitis to improve inflammatory control
These projects reflect a broader effort to refine treatment for common allergic and inflammatory conditions that affect quality of life.
Metabolic, Musculoskeletal, and Neurologic Conditions
The clinical trial portfolio also includes nutritional and metabolic diseases and musculoskeletal diseases, along with selected nervous system diseases. Key areas include hypercholesterolemia, overweight or obesity and knee osteoarthritis, early Parkinson’s disease, and myotonic dystrophy type 1, with studies aimed at improving disease management and patient outcomes.
- Trials in hypercholesterolemia and cardiovascular risk reduction
- Research in overweight or obesity and knee osteoarthritis focused on weight control and pain relief
- Studies in early Parkinson’s disease and myotonic dystrophy type 1 exploring symptom improvement
This mix of research shows a broad interest in chronic conditions where better long-term treatment options are still needed.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 71 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 66 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
- 1Novo Nordisk A/S2active
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario Infanta Sofía
lock Showing 1 of 38 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter randomized, double-blind, placebo-controlled Phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP) / NEPTUNE-17. | Glaxosmithkline Research & Development Limited | Phase II | Not Recruiting | Dec 2023 | Oct 2024 |
IMP list
lock Showing 1 of 71 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Emtricitabine | 3 | Unknown | 2023-02-03 | 2024-05-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.